{"source_url": "https://www.fiercepharma.com", "url": "https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data?utm_source=internal&utm_medium=rss", "title": "Regeneron builds preventive case for Eylea with new 2-year data", "top_image": "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87", "meta_img": "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87", "images": ["https://qtxasset.com/styles/content_well_thumb/s3/fiercepharma/1581434681/d587730a-b995-4f8a-bf6f-1731b10bd7c0.HR_.jpg/d587730a-b995-4f8a-bf6f-1731b10bd7c0.HR_.jpg?jaKPBp_YawkkX5Pl_y0zLhh0yCd3FVCu&itok=EPKwUH5I", "https://www.fiercepharma.com/themes/custom/tektite/assets/images/footer-questex.svg", "https://qtxasset.com/styles/content_well_thumb/s3/fiercepharma/1581435950/Novartis.jpg/Novartis.jpg?Efh8gVn0BZKq2I1x9CDtFnuPPWJC0cnw&itok=1jbNPy3D", "https://qtxasset.com/styles/breakpoint_sm_default_480px_w/s3/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?9BjyxRs5fZtS_Qkf9WoJIonRi8XAl88A&itok=GVWvEsIf", "https://www.fiercepharma.com/themes/custom/tektite_fierce/assets/images/logo/logo-pharma.svg?v=1", "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87", "https://www.fiercepharma.com/themes/custom/tektite/assets/images/logo-questex.svg", "https://qtxasset.com/styles/content_well_thumb/s3/fiercepharma/1581435301/akorn-7.jpg/akorn-7.jpg?MbXqHXP5NsMctjNxUfAdFOsu7oYg6vH9&itok=KLHa9MW0"], "movies": [], "text": "Despite facing a highly touted competitor in Novartis' Beovu, Regeneron hasn't broken a sweat as blockbuster eye med Eylea continues to gobble up market share. Already in the lead in multiple indications, new two-year data could help Regeneron make the case for its drug in the preventive setting as well.\n\nAfter two years, injectable Eylea sliced the risk of vision-threatening complications by 75% over placebo in patients with non-proliferative diabetic retinopathy, according to phase 3 data released Friday.\n\nRegeneron touted the data as a case for physicians to use Eylea preventively, as 58% of patients in the phase 3 Panorama trial's control arm developed diabetic macular edema or compromised vision at the two-year mark.\n\nThe FDA approved Eylea in May to treat all stages of diabetic retinopathy, a condition that affects about 8 million people worldwide and is the leading cause of blindness in U.S. adults, the company said.\n\nThe administration based its nod on six- and 12-month data from the Panorama study showing Eylea significantly cut the risk of patients developing proliferative diabetic retinopathy when treated every eight and 16 weeks.\n\nRELATED: Can Regeneron weather Novartis' Eylea rival and Praluent new deal? No worries, says exec", "keywords": [], "meta_keywords": ["Eylea", "Regeneron Pharmaceuticals", "age-related macular degeneration"], "tags": ["age-related macular degeneration"], "authors": ["Kyle Blankenship"], "publish_date": null, "summary": "", "article_html": "", "meta_description": "Despite facing a highly touted competitor in Novartis' Beovu, Regeneron hasn't broken a sweat as blockbuster eye med Eylea continues to gobble up the market. Already in the lead in multiple indications, new two-year data could help Regeneron make the case for its drug in the preventive setting as well.", "meta_lang": "en", "meta_favicon": "/themes/custom/tektite_fierce/favicon.ico", "meta_data": {"og": {"site_name": "FiercePharma", "url": "https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data", "title": "Regeneron builds preventive case for Eylea with new 2-year data", "description": "Despite facing a highly touted competitor in Novartis' Beovu, Regeneron hasn't broken a sweat as blockbuster eye med Eylea continues to gobble up the market. Already in the lead in multiple indications, new two-year data could help Regeneron make the case for its drug in the preventive setting as well.", "image": {"identifier": "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87", "secure_url": "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87"}}, "twitter": {"card": "summary_large_image", "description": "Despite facing a highly touted competitor in Novartis' Beovu, Regeneron hasn't broken a sweat as blockbuster eye med Eylea continues to gobble up the market. Already in the lead in multiple indications, new two-year data could help Regeneron make the case for its drug in the preventive setting as well.", "title": "Regeneron builds preventive case for Eylea with new 2-year data", "url": "https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data", "image": "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87"}, "news_keywords": "Eylea, Regeneron Pharmaceuticals,age-related macular degeneration", "description": "Despite facing a highly touted competitor in Novartis' Beovu, Regeneron hasn't broken a sweat as blockbuster eye med Eylea continues to gobble up the market. Already in the lead in multiple indications, new two-year data could help Regeneron make the case for its drug in the preventive setting as well.", "keywords": "Eylea, Regeneron Pharmaceuticals,age-related macular degeneration", "article": {"tag": "age-related macular degeneration"}, "gtm-keywords": "Eylea, Regeneron Pharmaceuticals", "gtm-article": 456116, "parsely-tags": "age-related macular degeneration", "gtm-topics": "age-related macular degeneration", "parsely-section": "Pharma", "parsely-title": "Regeneron builds preventive case for Eylea with new 2-year data", "gtm-contenttype": "Article", "gtm-section": "Pharma", "parsely-post-id": 456116, "parsely-author": "Kyle Blankenship", "parsely-image-url": "https://qtxasset.com/fiercepharma/1581345626/Eylea.jpg/Eylea.jpg?ujd.RUduH.DadgY7j58zCtnafODS5E87", "parsely-type": "post", "parsely-pub-date": "2020-02-10T10:54:00-0500", "parsely-link": "https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data", "Generator": "Drupal 8 (https://www.drupal.org)", "MobileOptimized": "width", "HandheldFriendly": "true", "viewport": "width=device-width, initial-scale=1.0", "msapplication-TileColor": "#da532c", "msapplication-TileImage": "/themes/custom/tektite_fierce/mstile-144x144.png?v=wAAmkK2yLl", "theme-color": "#ffffff"}, "canonical_link": "https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data"}